Karima Relizani

650 total citations
19 papers, 521 citations indexed

About

Karima Relizani is a scholar working on Molecular Biology, Physiology and Genetics. According to data from OpenAlex, Karima Relizani has authored 19 papers receiving a total of 521 indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Molecular Biology, 5 papers in Physiology and 4 papers in Genetics. Recurrent topics in Karima Relizani's work include Muscle Physiology and Disorders (10 papers), CRISPR and Genetic Engineering (8 papers) and RNA Interference and Gene Delivery (6 papers). Karima Relizani is often cited by papers focused on Muscle Physiology and Disorders (10 papers), CRISPR and Genetic Engineering (8 papers) and RNA Interference and Gene Delivery (6 papers). Karima Relizani collaborates with scholars based in France, Germany and Monaco. Karima Relizani's co-authors include Luis Garcı́a, Aurélie Goyenvalle, Lucía Echevarría, Helge Amthor, Étienne Mouisel, Markus Schuelke, Arnaud Ferry, Cyrille Vaillend, Susanne Morales-Gonzalez and Rebeca Martín and has published in prestigious journals such as Nucleic Acids Research, Annals of Neurology and Scientific Reports.

In The Last Decade

Karima Relizani

19 papers receiving 517 citations

Peers

Karima Relizani

PHYSI

GENET

Katrin Hollinger United States

M. V. Dodson United States

Mônica Senna Salerno New Zealand

Ferenc Jeanplong New Zealand

M Terada Japan

Anne‐Sophie Arnold United States

M. G. Ashby New Zealand

Haorong He China

Sean M. Garvey United States

Camila de Almeida Brazil

Katrin Hollinger United States

Karima Relizani

339 ×0.8

142 ×1.1

PHYSI

94 ×1.1

GENET

44 ×0.7

51 ×1.0

GENET

Citations per year, relative to Karima Relizani Karima Relizani (= 1×) peers Katrin Hollinger

Countries citing papers authored by Karima Relizani

Since Specialization

Citations

This map shows the geographic impact of Karima Relizani's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Karima Relizani with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Karima Relizani more than expected).

Fields of papers citing papers by Karima Relizani

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Karima Relizani. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Karima Relizani. The network helps show where Karima Relizani may publish in the future.

Co-authorship network of co-authors of Karima Relizani

This figure shows the co-authorship network connecting the top 25 collaborators of Karima Relizani. A scholar is included among the top collaborators of Karima Relizani based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Karima Relizani. Karima Relizani is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

Relizani, Karima, Camille Kropp, Rebeca Martín, et al.. (2022). Selection of a novel strain of Christensenella minuta as a future biotherapy for Crohn’s disease. Scientific Reports. 12(1). 6017–6017. 24 indexed citations

Relizani, Karima, et al.. (2022). Partial Restoration of Brain Dystrophin and Behavioral Deficits by Exon Skipping in the Muscular Dystrophy X‐Linked (mdx) Mouse. Annals of Neurology. 92(2). 213–229. 16 indexed citations

Kropp, Camille, Karima Relizani, Florian Chain, et al.. (2021). The Keystone commensal bacterium Christensenella minuta DSM 22607 displays anti-inflammatory properties both in vitro and in vivo. Scientific Reports. 11(1). 11494–11494. 67 indexed citations

Relizani, Karima, Lucía Echevarría, Thibaut Larcher, et al.. (2021). Palmitic acid conjugation enhances potency of tricyclo-DNA splice switching oligonucleotides. Nucleic Acids Research. 50(1). 17–34. 30 indexed citations

Stantzou, Amalia, Karima Relizani, Susanne Morales-Gonzalez, et al.. (2020). Extracellular matrix remodelling is associated with muscle force increase in overloaded mouse plantaris muscle. Neuropathology and Applied Neurobiology. 47(2). 218–235. 12 indexed citations

Echevarría, Lucía, Karima Relizani, Graziella Griffith, et al.. (2019). Evaluating the Impact of Variable Phosphorothioate Content in Tricyclo-DNA Antisense Oligonucleotides in a Duchenne Muscular Dystrophy Mouse Model. Nucleic Acid Therapeutics. 29(3). 148–160. 21 indexed citations

Echevarría, Lucía, Karima Relizani, Grégory Jouvion, et al.. (2019). Identifying and Avoiding tcDNA-ASO Sequence-Specific Toxicity for the Development of DMD Exon 51 Skipping Therapy. Molecular Therapy — Nucleic Acids. 19. 371–383. 20 indexed citations

Relizani, Karima, et al.. (2019). AAV Production Using Baculovirus Expression Vector System. Methods in molecular biology. 1937. 91–99. 17 indexed citations

Relizani, Karima & Aurélie Goyenvalle. (2018). Use of Tricyclo-DNA Antisense Oligonucleotides for Exon Skipping. Methods in molecular biology. 1828. 381–394. 9 indexed citations

10.

Relizani, Karima & Aurélie Goyenvalle. (2017). The Use of Antisense Oligonucleotides for the Treatment of Duchenne Muscular Dystrophy. Methods in molecular biology. 1687. 171–183. 4 indexed citations

11.

Relizani, Karima, Graziella Griffith, Lucía Echevarría, et al.. (2017). Efficacy and Safety Profile of Tricyclo-DNA Antisense Oligonucleotides in Duchenne Muscular Dystrophy Mouse Model. Molecular Therapy — Nucleic Acids. 8. 144–157. 61 indexed citations

12.

Echevarría, Lucía, et al.. (2017). The Use of Tricyclo-DNA Oligomers for the Treatment of Genetic Disorders. Biomedicines. 6(1). 2–2. 19 indexed citations

13.

Relizani, Karima, et al.. (2016). Rapid, scalable, and low-cost purification of recombinant adeno-associated virus produced by baculovirus expression vector system. Molecular Therapy — Methods & Clinical Development. 3. 16035–16035. 17 indexed citations

14.

Petkova, Mina, Susanne Morales-Gonzalez, Karima Relizani, et al.. (2016). Characterization of a Dmd EGFP reporter mouse as a tool to investigate dystrophin expression. Skeletal Muscle. 6(1). 25–25. 15 indexed citations

15.

Pecchi, Émilie, Karima Relizani, Christophe Vilmen, et al.. (2016). Mitochondrial impairment induced by postnatal ActRIIB blockade does not alter function and energy status in exercising mouse glycolytic muscle in vivo. American Journal of Physiology-Endocrinology and Metabolism. 310(7). E539–E549. 10 indexed citations

16.

Relizani, Karima, Étienne Mouisel, Benoı̂t Giannesini, et al.. (2014). Blockade of ActRIIB Signaling Triggers Muscle Fatigability and Metabolic Myopathy. Molecular Therapy. 22(8). 1423–1433. 61 indexed citations

17.

Mouisel, Étienne, Karima Relizani, Laurence Mille-Hamard, et al.. (2014). Myostatin is a key mediator between energy metabolism and endurance capacity of skeletal muscle. American Journal of Physiology-Regulatory, Integrative and Comparative Physiology. 307(4). R444–R454. 65 indexed citations

18.

Relizani, Karima, et al.. (2014). Combinatory effects of siRNA-induced myostatin inhibition and exercise on skeletal muscle homeostasis and body composition. Physiological Reports. 2(3). e00262–e00262. 22 indexed citations

19.

Hoogaars, Willem M.H., Étienne Mouisel, Arja Pasternack, et al.. (2012). Combined Effect of AAV-U7-Induced Dystrophin Exon Skipping and Soluble Activin Type IIB Receptor in mdx Mice. Human Gene Therapy. 23(12). 1269–1279. 31 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact